Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Arcturus Therapeutics Ltd (ARCT)

Arcturus Therapeutics Ltd (ARCT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 483,204
  • Shares Outstanding, K 26,419
  • Annual Sales, $ 12,400 K
  • Annual Income, $ -203,700 K
  • 60-Month Beta 2.79
  • Price/Sales 35.88
  • Price/Cash Flow N/A
  • Price/Book 1.45
Trade ARCT with:

Options Overview Details

View History
  • Implied Volatility 122.68% ( +5.03%)
  • Historical Volatility 132.80%
  • IV Percentile 76%
  • IV Rank 61.20%
  • IV High 153.83% on 12/13/21
  • IV Low 73.54% on 06/17/21
  • Put/Call Vol Ratio 0.03
  • Today's Volume 425
  • Volume Avg (30-Day) 681
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 25,783
  • Open Int (30-Day) 20,753

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -1.84
  • Number of Estimates 4
  • High Estimate -1.54
  • Low Estimate -2.04
  • Prior Year -2.07
  • Growth Rate Est. (year over year) +11.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.12 +36.72%
on 05/12/22
26.19 -36.73%
on 04/19/22
-8.67 (-34.35%)
since 04/18/22
3-Month
12.12 +36.72%
on 05/12/22
31.41 -47.25%
on 04/05/22
-5.96 (-26.45%)
since 02/18/22
52-Week
12.12 +36.72%
on 05/12/22
65.00 -74.51%
on 08/10/21
-14.25 (-46.24%)
since 05/18/21

Most Recent Stories

More News
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue Estimates

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -50.39% and 60.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ARCT : 16.57 (-9.40%)
KMDA : 4.66 (-5.48%)
Arcturus Therapeutics Announces First Quarter 2022 Financial Update and Pipeline Progress

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines...

ARCT : 16.57 (-9.40%)
Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines...

ARCT : 16.57 (-9.40%)
Arcturus Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on May 9, 2022

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines...

ARCT : 16.57 (-9.40%)
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a late-stage global clinical messenger RNA medicines company focused on the development of infectious disease vaccines...

ARCT : 16.57 (-9.40%)
Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines...

ARCT : 16.57 (-9.40%)
Arcturus Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and...

ARCT : 16.57 (-9.40%)
Arcturus Therapeutics (ARCT) Surges 7.2%: Is This an Indication of Further Gains?

Arcturus Therapeutics (ARCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price...

ARCT : 16.57 (-9.40%)
BMY : 77.02 (-1.53%)
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and...

ARCT : 16.57 (-9.40%)
Notable Friday Option Activity: ARCT, DISH, ZS

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Arcturus Therapeutics Holdings Inc , where a total volume of 2,543 contracts has been...

ARCT : 16.57 (-9.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Arcturus Therapeutics Ltd. is a preclinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of RNA medicines using proprietary lipid-mediated delivery system LUNAR(TM) and UNA Oligomer chemistry technologies. Arcturus Therapeutics Ltd, formerly known as...

See More

Key Turning Points

3rd Resistance Point 19.51
2nd Resistance Point 18.73
1st Resistance Point 17.65
Last Price 16.57
1st Support Level 15.79
2nd Support Level 15.01
3rd Support Level 13.93

See More

52-Week High 65.00
Fibonacci 61.8% 44.80
Fibonacci 50% 38.56
Fibonacci 38.2% 32.32
Last Price 16.57
52-Week Low 12.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar